Biomea Fusion (BMEA) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
PolyPid (PYPD) has outperformed Biomea Fusion (BMEA) over the past year, gaining 42.9% versus a loss of 18.5%. Over five years, BMEA leads with a -88.2% price change compared with -97.8% for PYPD. PolyPid is the larger company by market cap ($99.5 million vs $99.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | PYPD |
|---|---|---|
| Share price | $1.37 | $4.90 |
| Market cap | $99.05M | $99.53M |
| 1-day change | +3.79% | -1.01% |
| YTD return | +10.48% | +12.90% |
| 1-year return | -18.45% | +42.86% |
| 5-year return | -88.22% | -97.83% |
| EPS (TTM) | $-0.29 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $5.73 |
| 52-week low | $0.872 | $3.06 |
| Distance from 52-week high | -38.76% | -14.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +410.95% | +139.80% |
| Average volume | 1.47M | 180.34K |
| Shares outstanding | 72.30M | 20.31M |
| Employees | 37 | 69 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed BMEA by 61.3 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Healthcare · Biotechnology · 37 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Healthcare · Biotechnology · 69 employees
BMEA vs PYPD FAQ
Which is bigger, Biomea Fusion or PolyPid?
PolyPid (PYPD) is larger, with a market capitalization of $99.53M compared with $99.05M for Biomea Fusion (BMEA).
Which stock has performed better over the past year, BMEA or PYPD?
PYPD returned +42.86% over the past 12 months, compared with -18.45% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and PolyPid in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.